Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.

PHASE1RecruitingINTERVENTIONAL

Enrollment

120

Participants

Timeline

Start Date

February 3, 2019

Primary Completion Date

April 10, 2026

Study Completion Date

April 10, 2026

Conditions

FibromyalgiaChronic Fatigue SyndromeMultiple SclerosisHealthy

Interventions

DRUG

DPA-714 PET/MRI

Trial Locations (1)

RECRUITING

University of Alabama at Birmingham Medical Center, Birmingham

All Listed Sponsors

lead

University of Alabama at Birmingham

OTHER

NCT03759522 - Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714. | Biotech Hunter | Biotech Hunter